Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free MDLN Stock Alerts

Medline (MDLN) Competitors

Medline logo
$35.61 +0.67 (+1.92%)
Closing price 10/2/2026 04:00 PM Eastern
Extended Trading
$35.32 -0.29 (-0.81%)
As of 10/2/2026 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

MDLN vs. ALC, WST, SOLV, COO, and ALGN

Should you buy Medline stock or one of its competitors? Medline's main competitors and comparable companies include Alcon (ALC), West Pharmaceutical Services (WST), Solventum (SOLV), Cooper Companies (COO), and Align Technology (ALGN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare supplies" industry.

How does Medline compare to Alcon?

Medline (NASDAQ:MDLN) and Alcon (NYSE:ALC) are both large-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings.

Alcon has a net margin of 5.92% compared to Medline's net margin of 0.00%. Alcon's return on equity of 7.29% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
MedlineN/A N/A N/A
Alcon 5.92%7.29%5.09%

53.9% of Alcon shares are owned by institutional investors. 0.8% of Medline shares are owned by company insiders. Comparatively, 1.5% of Alcon shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Medline currently has a consensus target price of $46.88, suggesting a potential upside of 31.66%. Alcon has a consensus target price of $84.97, suggesting a potential upside of 33.30%. Given Alcon's higher probable upside, analysts clearly believe Alcon is more favorable than Medline.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline
1 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.83
Alcon
1 Sell rating(s)
6 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.63

In the previous week, Medline had 7 more articles in the media than Alcon. MarketBeat recorded 13 mentions for Medline and 6 mentions for Alcon. Alcon's average media sentiment score of 0.26 beat Medline's score of 0.10 indicating that Alcon is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medline
1 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alcon
2 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Medline has higher revenue and earnings than Alcon. Medline is trading at a lower price-to-earnings ratio than Alcon, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medline$28.43B1.65$1.16B$0.7945.08
Alcon$10.40B3.03$980M$1.3148.66

Summary

Alcon beats Medline on 10 of the 16 factors compared between the two stocks.

How does Medline compare to West Pharmaceutical Services?

West Pharmaceutical Services (NYSE:WST) and Medline (NASDAQ:MDLN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, risk, valuation, analyst recommendations and earnings.

In the previous week, Medline had 11 more articles in the media than West Pharmaceutical Services. MarketBeat recorded 13 mentions for Medline and 2 mentions for West Pharmaceutical Services. West Pharmaceutical Services' average media sentiment score of 0.45 beat Medline's score of 0.10 indicating that West Pharmaceutical Services is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
West Pharmaceutical Services
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Medline
1 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Medline has higher revenue and earnings than West Pharmaceutical Services. Medline is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
West Pharmaceutical Services$3.07B8.37$493.70M$7.8146.81
Medline$28.43B1.65$1.16B$0.7945.08

West Pharmaceutical Services has a net margin of 16.98% compared to Medline's net margin of 0.00%. West Pharmaceutical Services' return on equity of 20.11% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
West Pharmaceutical Services16.98% 20.11% 14.83%
Medline N/A N/A N/A

West Pharmaceutical Services currently has a consensus price target of $382.00, indicating a potential upside of 4.50%. Medline has a consensus price target of $46.88, indicating a potential upside of 31.66%. Given Medline's higher probable upside, analysts clearly believe Medline is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
West Pharmaceutical Services
0 Sell rating(s)
2 Hold rating(s)
12 Buy rating(s)
0 Strong Buy rating(s)
2.86
Medline
1 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.83

93.9% of West Pharmaceutical Services shares are owned by institutional investors. 0.6% of West Pharmaceutical Services shares are owned by insiders. Comparatively, 0.8% of Medline shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

West Pharmaceutical Services beats Medline on 9 of the 16 factors compared between the two stocks.

How does Medline compare to Solventum?

Solventum (NYSE:SOLV) and Medline (NASDAQ:MDLN) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Solventum has higher earnings, but lower revenue than Medline. Solventum is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Solventum$8.33B1.80$1.56B$8.1810.76
Medline$28.43B1.65$1.16B$0.7945.08

In the previous week, Medline had 10 more articles in the media than Solventum. MarketBeat recorded 13 mentions for Medline and 3 mentions for Solventum. Solventum's average media sentiment score of 0.47 beat Medline's score of 0.10 indicating that Solventum is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Solventum
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Medline
1 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Solventum currently has a consensus target price of $92.80, indicating a potential upside of 5.48%. Medline has a consensus target price of $46.88, indicating a potential upside of 31.66%. Given Medline's stronger consensus rating and higher probable upside, analysts clearly believe Medline is more favorable than Solventum.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solventum
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.58
Medline
1 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.83

Solventum has a net margin of 17.26% compared to Medline's net margin of 0.00%. Solventum's return on equity of 25.09% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
Solventum17.26% 25.09% 8.78%
Medline N/A N/A N/A

Summary

Solventum and Medline tied by winning 7 of the 14 factors compared between the two stocks.

How does Medline compare to Cooper Companies?

Medline (NASDAQ:MDLN) and Cooper Companies (NASDAQ:COO) are both large-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

Medline has higher revenue and earnings than Cooper Companies. Cooper Companies is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medline$28.43B1.65$1.16B$0.7945.08
Cooper Companies$4.09B2.64$374.90M$2.9319.42

Cooper Companies has a net margin of 13.46% compared to Medline's net margin of 0.00%. Cooper Companies' return on equity of 10.90% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
MedlineN/A N/A N/A
Cooper Companies 13.46%10.90%7.24%

24.4% of Cooper Companies shares are held by institutional investors. 0.8% of Medline shares are held by insiders. Comparatively, 2.1% of Cooper Companies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Medline currently has a consensus price target of $46.88, suggesting a potential upside of 31.66%. Cooper Companies has a consensus price target of $71.47, suggesting a potential upside of 25.58%. Given Medline's stronger consensus rating and higher possible upside, analysts plainly believe Medline is more favorable than Cooper Companies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Medline
1 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.83
Cooper Companies
2 Sell rating(s)
12 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.16

In the previous week, Cooper Companies had 19 more articles in the media than Medline. MarketBeat recorded 32 mentions for Cooper Companies and 13 mentions for Medline. Cooper Companies' average media sentiment score of 0.25 beat Medline's score of 0.10 indicating that Cooper Companies is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Medline
1 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cooper Companies
4 Very Positive mention(s)
5 Positive mention(s)
9 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Cooper Companies beats Medline on 9 of the 16 factors compared between the two stocks.

How does Medline compare to Align Technology?

Align Technology (NASDAQ:ALGN) and Medline (NASDAQ:MDLN) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, profitability, media sentiment, valuation, dividends, earnings, institutional ownership and analyst recommendations.

88.4% of Align Technology shares are owned by institutional investors. 0.8% of Align Technology shares are owned by company insiders. Comparatively, 0.8% of Medline shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Medline has higher revenue and earnings than Align Technology. Align Technology is trading at a lower price-to-earnings ratio than Medline, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Align Technology$4.03B2.55$410.35M$5.7525.00
Medline$28.43B1.65$1.16B$0.7945.08

Align Technology presently has a consensus target price of $206.36, indicating a potential upside of 43.56%. Medline has a consensus target price of $46.88, indicating a potential upside of 31.66%. Given Align Technology's higher probable upside, analysts clearly believe Align Technology is more favorable than Medline.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Align Technology
0 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
1 Strong Buy rating(s)
2.67
Medline
1 Sell rating(s)
5 Hold rating(s)
21 Buy rating(s)
2 Strong Buy rating(s)
2.83

Align Technology has a net margin of 9.99% compared to Medline's net margin of 0.00%. Align Technology's return on equity of 15.86% beat Medline's return on equity.

Company Net Margins Return on Equity Return on Assets
Align Technology9.99% 15.86% 10.32%
Medline N/A N/A N/A

In the previous week, Medline had 6 more articles in the media than Align Technology. MarketBeat recorded 13 mentions for Medline and 7 mentions for Align Technology. Align Technology's average media sentiment score of 0.32 beat Medline's score of 0.10 indicating that Align Technology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Align Technology
1 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Medline
1 Very Positive mention(s)
1 Positive mention(s)
10 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Align Technology and Medline tied by winning 8 of the 16 factors compared between the two stocks.

Get Medline News Delivered to You Automatically

Sign up to receive the latest news and ratings for MDLN and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDLN vs. The Competition

Export
MetricMedlineHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$45.94B$5.43B$7.14B$13.22B
Dividend YieldN/A1.80%2.53%16.78%
P/E Ratio45.0824.90275.9726.04
Price / Sales1.6584.79672.88109.45
Price / Cash20.6032.4377.6051.75
Price / Book2.435.7310.936.31
Net Income$1.16B$152.68M$3.51B$362.16M
7 Day Performance2.62%-1.71%-2.00%-1.66%
1 Month Performance-2.68%-4.81%-6.15%-4.50%
1 Year PerformanceN/A1.08%7.44%2.06%

Medline Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MDLN
Medline
2.9526 of 5 stars		$35.61
+1.9%		$46.88
+31.7%		N/A$45.94B$28.43B45.0845,000
ALC
Alcon
3.3924 of 5 stars		$64.51
-1.4%		$84.97
+31.7%		-15.1%$31.92B$10.86B49.2625,942
WST
West Pharmaceutical Services
2.8097 of 5 stars		$377.81
+0.5%		$382.00
+1.1%		+33.7%$26.58B$3.33B48.3510,800
SOLV
Solventum
1.7503 of 5 stars		$88.56
+0.2%		$92.80
+4.8%		+18.0%$15.08B$8.31B10.8320,000
COO
Cooper Companies
4.1805 of 5 stars		$55.20
-1.6%		$71.47
+29.5%		-17.7%$10.49B$4.24B18.8215,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MDLN) was last updated on 10/3/2026 by MarketBeat.com Staff.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel